Scholarlink

Background <p>Enchondroma is a benign, cartilaginous tumour and is the most common bone tumour of the hand. Lesions are typically asymptomatic or have only mild symptoms and are commonly diagnosed following a pathological fracture. Surgical treatment is reserved for symptomatic lesions and involves curettage of the bony lesion followed by augmentation of the defect with autologous bone graft or artificial bone substituent.</p> Methods <p>A systematic review was conducted with the aim of comparing the outcomes between autologous bone graft and artificial bone substituents when used for management of enchondroma of the hand. Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines were adopted in performing this systematic review.</p> Results <p>The review identified 25 studies, reporting a total of 830 patients undergoing surgical management of enchondroma in the hand with either autologous bone graft or artificial bone substituent. Autologous bone grafting was investigated in 14 studies (<i>n</i> = 442 patients). Artificial bone substituents were investigated in 15 studies (<i>n</i> = 388 patients). The mean age for patients that underwent autologous bone grafting was 37 years and the mean age for patients undergoing artificial bone substituent grafting was 35 years. Mean follow-up was 43 months for autologous graft and 21 months for artificial bone substituent. An overall complication rate of 17% was reported for the entire cohort. The complication rate for autologous grafting was 20% and the complication rate for artificial bone substituent was 13%. Full range of motion was achieved in 94% of patients managed with autologous bone graft and in 95% of patients managed with artificial bone substituents.</p> Conclusions <p>Autologous bone graft and artificial bone substituent are both safe and effective options for management of enchondroma in the hand. Complication rate was lower in patients managed with artificial bone substituents and post-operative function was similar in both cohorts.</p> <p>Level of Evidence: Not gradable.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A systematic review of autologous bone grafting versus artificial bone substituents for the management of enchondroma in the hand

  • 期刊论文

  • 发表日期：

    2025年4月4日

查看全文
  • Anton I. Alvaro,
  • Timothy R. Chew,
  • Nicholas W. Smith

摘要

Background

Enchondroma is a benign, cartilaginous tumour and is the most common bone tumour of the hand. Lesions are typically asymptomatic or have only mild symptoms and are commonly diagnosed following a pathological fracture. Surgical treatment is reserved for symptomatic lesions and involves curettage of the bony lesion followed by augmentation of the defect with autologous bone graft or artificial bone substituent.

Methods

A systematic review was conducted with the aim of comparing the outcomes between autologous bone graft and artificial bone substituents when used for management of enchondroma of the hand. Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines were adopted in performing this systematic review.

Results

The review identified 25 studies, reporting a total of 830 patients undergoing surgical management of enchondroma in the hand with either autologous bone graft or artificial bone substituent. Autologous bone grafting was investigated in 14 studies (n = 442 patients). Artificial bone substituents were investigated in 15 studies (n = 388 patients). The mean age for patients that underwent autologous bone grafting was 37 years and the mean age for patients undergoing artificial bone substituent grafting was 35 years. Mean follow-up was 43 months for autologous graft and 21 months for artificial bone substituent. An overall complication rate of 17% was reported for the entire cohort. The complication rate for autologous grafting was 20% and the complication rate for artificial bone substituent was 13%. Full range of motion was achieved in 94% of patients managed with autologous bone graft and in 95% of patients managed with artificial bone substituents.

Conclusions

Autologous bone graft and artificial bone substituent are both safe and effective options for management of enchondroma in the hand. Complication rate was lower in patients managed with artificial bone substituents and post-operative function was similar in both cohorts.

Level of Evidence: Not gradable.